The beneficial effects of modest weight loss on cardiovascular risk factors

International Journal of Obesity

Volumn 21, Issue SUPPL. 1, 1997, Pages

  Van Gaal, L F ^a   Wauters, M A ^a   De Leeuw, I H ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Cardiovascular risk factors; Haemostatic factors; Lipids; Lipoproteins; Weight loss

Indexed keywords

BLOOD CLOTTING FACTOR 7; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN; LIPOPROTEIN A; PLASMINOGEN ACTIVATOR INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL;

ARTERY LESION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONFERENCE PAPER; CONTROLLED STUDY; CORONARY ARTERY; EXERCISE; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; LIFESTYLE; LIPID BLOOD LEVEL; LIPID OXIDATION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

CARDIOVASCULAR DISEASES; CHOLESTEROL; HEMOSTASIS; HUMANS; LIFE STYLE; LIPID METABOLISM; LIPIDS; LIPOPROTEINS; MALE; MORBIDITY; OXIDATION-REDUCTION; RISK FACTORS; TRIGLYCERIDES; WEIGHT LOSS;

EID: 0030934629     PISSN: 03070565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (28)

1. Van Itallie TB. Health implications of overweight and obesity in the US. Ann Intern Med 1985; 103: 983-988.
2. Kluthe R, Schubert A. Obesity in Europe. Ann Intern Med 1995; 103: 1037-1042.
3. Peiris AN et al. Splanchnic insulin metabolism in obesity. Influence of body fat distribution. J Clin Invest 1986; 78:1648-1657.
4. Pi-Sunyer FX. Medical hazards of obesity. Ann Intern Med 1993; 119: 655-660.
5. Goldstein DJ. Beneficial effects of modest weight loss. Int J Obes 1992; 16: 397-415.
6. Kaplan RM et al. Prospective evaluation of HDL cholesterol after diet and physical conditioning programs for patients with type II diabetes mellitus. Diabetes Care 1985; 8: 343-348.
7. Wood PD et al. Changes in plasma lipids and lipoproteins in overweight men during weight loss through dieting as compared with exercise. N Engl J Med 1988; 319: 1173-1179.
8. Wood P, Stefanick ML, Williams PT, Haskell WL. The effects on plasma lipoproteins of a prudent weight-reducing diet, with or without exercise, in overweight men and women. N Engl J Med 1991; 325: 461-466.
9. Wing R et al. Long-term effects of modest weight loss in type II diabetic patients. Arch Intern Med 1987; 147: 1749-1753.
10. Steinberg D. Antioxidants in the prevention of human artheriosclerosis. Circulation 1992; 85: 2337-2345.
11. Zhang A, Verommen J, Van Gaal L, De Leeuw IH. A rapid and simple method for measuring the susceptibility of low density and very low density lipoproteins to copper-catalysed oxidation. Clin Chem Acta 1994; 227: 159-173.
12. Van Gaal LF, Zhang A, Steijaert MM, De Leeuw IH. Human obesity: from lipid abnormalities to lipid oxidation. Int J Obes Suppl 1995; 19 (3): S21-S26.
13. Després JP. Abdominal obesity as an important component of insulin-resistance syndrome. Nutrition 1993; 9: 452-459.
14. Scanu AM, Fless GM. Lipoprotein(a): heterogeneity and biological relevance. J Clin Invest 1990; 85: 1709-1715.
15. Mbewu AD, Durrington PN. Lipoprotein(a): structure, properties and possible involvement in thrombogenesis and atherogenesis. Atherosclerosis 1990; 85: 1-14.
16. Muls E et al. The effects of weight loss and apolipoprotein E polymorphism on serum lipids, apolipoproteins A-1 and B, and lipoprotein(a). Int J Obes 1993; 17: 711-716.
17. Kannel WB, Wolf PA, Castelli WP, Agostino R. Fibrinogen and risks of cardiovascular disease: the Framingham study. JAMA 1987; 258: 1183-1186.
18. Thompson SG et al. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 332: 635-641.
19. Primrose JN et al. Reduction in factor VII, fibrinogen and plasminogen activator inhibitor activity after surgical treatment of morbid obesity. Thromb Haemost 1992; 68: 396-439.
20. Folsom AR et al. Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII, and other hemostatic factors in moderately overweight adults. Arterioscler Thromb Vasc Biol 1993; 13: 162-169.
21. Rillaerts E et al. Blood viscosity in human obesity. Relation to glucose tolerance and insulin status. Int J Obes 1989; 13: 739-745.
22. Meade JW et al. Haemostatic function and ischemic heart disease: principal results of the Northwick Park Study. Lancet 1986; 2: 533-537.
23. Hamsten A, Wiman B, De Faire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313: 1557-1563.
24. Vague P et al. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level and relative body weight in normal and obese subjects. Metabolism 1986; 35: 250-253.
25. Vague P et al. Fat distribution and plasminogen activator inhibitor in nondiabetic obese women. Metabolism 1989; 38: 913-915.
26. Velthius-te Wierik E et al. Beneficial effect of a moderately energy-restricted diet on fibrinolytic factors in non-obese men. Metabolism 1995; 44: 1548-1552.
27. Ornish D et al. Can lifestyle changes reverse coronary heart disease? Lancet 1990; 336: 129-133.
28. Singh R et al. Randomised controlled trial of cardioprotective diet in patients with recent acute myocardial infarction: results of one year follow-up. BMJ 1992; 304: 1015-1019.